Evotec - Research never stops
  • Loading...

Ono

The collaboration applies Evotec's proprietary fragment-based drug discovery platform, EVOlution™ to identify novel, small molecular weight compounds active against a protease target. The platform integrates, among other things, protein X-ray crystallography, computational chemistry, structural biology, biochemical, and NMR-based fragment screening in combination with its high quality fragment libraries. In the collaboration it is combined with Evotec's expertise in medicinal chemistry and ADMET to further characterize active compounds identified and optimize their potency and selectivity to generate molecules for subsequent progression into clinical trials.

14 Dec 2009
Evotec Achieves Milestone in Medicinal Chemistry Collaboration with Ono Pharmaceutical Co., Ltd.

15 Oct 2009
Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical Co., Ltd.

27 Mar 2008
Ono Enters into a New Fragment-Based Drug Discovery Agreement with Evotec